Aldeyra Therapeutics, Inc. (ALDX)

Aldeyra Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	10.98	13.34	15.37	11.28	9.99	12.15
Research & Development	24.41	29.46	47.31	44.94	24.68	44.35
Other Operating Expenses	0	0	0	0	1.75	6.57
Operating Expenses	35.38	42.79	62.68	56.22	36.42	63.07
Operating Income	-35.38	-42.79	-62.68	-56.22	-36.42	-63.07
Interest Expense / Income	2.08	2.07	1.69	1.74	1.9	0.6
Other Expense / Income	-7.45	-7.32	-2.35	-0.19	-0.29	-1.54
Pretax Income	-30.01	-37.54	-62.02	-57.78	-38.03	-62.14
Income Tax	0	0	0	0	-0.48	-1.31
Net Income	-30.01	-37.54	-62.02	-57.78	-37.55	-60.83
Shares Outstanding (Basic)	59	59	58	54	34	27
Shares Outstanding (Diluted)	59	59	58	54	34	27
Shares Change	1.06%	0.92%	8.07%	59.11%	25.28%	25.02%
EPS (Basic)	-0.51	-0.64	-1.06	-1.07	-1.11	-2.24
EPS (Diluted)	-0.51	-0.64	-1.06	-1.07	-1.11	-2.24
Free Cash Flow	-30.85	-30.33	-56.65	-42.56	-37.49	-44.99
Free Cash Flow Per Share	-0.52	-0.51	-0.97	-0.79	-1.10	-1.66
EBITDA	-27.67	-35.21	-60.07	-55.77	-36.07	-61.44
Depreciation & Amortization	0.26	0.26	0.26	0.26	0.06	0.1
EBIT	-27.93	-35.47	-60.33	-56.03	-36.13	-61.53

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).